Skip to content
HealthNationWeekly insights

3-minute quiz

Are you a candidate for a GLP-1?

Eight straightforward questions. You'll get a clear readiness signal plus the next steps that make sense for your specific situation — whether that's a clinical conversation or a free lifestyle plan.

Step 1 of 7

The basics

Your age
Sex assigned at birth

This is informational only and is not a diagnosis. The result will be more useful the more honestly you answer.

How this quiz works

The quiz looks at three things: whether you meet the FDA-approved indication for a GLP-1 for chronic weight management (BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity), whether any contraindications apply, and where you sit on the motivation spectrum. The result is a readiness signal — not a prescription, not a diagnosis, not medical advice.

What we recommend

Regardless of bucket, the quiz finishes with concrete next steps. If you're a clinical candidate, we send you a vetted provider list. If you're not yet, we send you a tools-first 12-week plan that targets the highest-leverage levers (protein adequacy, sleep debt, training stimulus).

A note on compounded GLP-1s

HealthNation does not route to providers that exclusively prescribe compounded semaglutide or tirzepatide. We route only to FDA-approved drug pathways. Compounded GLP-1s are under active FDA enforcement and the quality varies dramatically by source. Read more in our monetization policy.

References

  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002.
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387(3):205-216.
  • FDA. Prescribing information for Wegovy (semaglutide injection) and Zepbound (tirzepatide injection).